On March 11, 2026, Ligand Pharmaceuticals (LGND 4.03%) Chief Financial Officer Octavio Espinoza reported the sale of 3,057 shares of common stock for a transaction value of approximately $688,000, according to a SEC Form 4 filing.Transaction summaryMetricValueShares sold (direct)3,057Transaction value$687,825.00Post-transaction common shares (direct)21,010Post-transaction value (direct ownership)~$4.65 millionTransaction value based on SEC Form 4 weighted average purchase price ($225.00); post-transaction v ...